ArticleFrontiers in immunology2022

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma.

Ying Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.